All research
Semaglutide 2026-09-02 PubMed

Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.


Summary withdrawn

TitrateLab removes an AI-written study summary when it states findings we cannot trace to the study's own record, or when the study falls outside the compounds we track. Read the original record through the link above.


semaglutide neuropsychiatric obesity t2dm glp-1-agonist cohort
Source: pubmed:42680805 · Ingested Sep 2, 2026